Search the Newsreel

Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to Hold at Wall Street Zen

Wall Street Zen has upgraded Unicycive Therapeutics (NASDAQ:UNCY) from a "sell" to a "hold" rating, contributing to a mixed analyst consensus of "Hold" with a $18.25 price target. Despite several firms like Benchmark and HC Wainwright maintaining bullish ratings but cutting price targets, and …

Wall Street Zen Upgrades Bicycle Therapeutics (NASDAQ:BCYC) to "Sell"

Cyclerion Therapeutics (CYCN): ADAR1 Capital discloses 7.0% beneficial ownership

ADAR1 Capital Management, LLC and Daniel Schneeberger have reported beneficial ownership of 7.0% of Cyclerion Therapeutics, Inc. (CYCN) common stock, totaling 298,757 shares. This ownership is held by private investment funds managed by ADAR1, with both reporting persons exercising shared voting and dispositive power. …

Nantahala Capital (UNCY) discloses 2.81M-share, 9.99% holding in Unicycive

Nantahala Capital Management, alongside Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 2,807,830 shares, representing 9.99% of Unicycive Therapeutics, Inc. common stock as of June 30, 2026. This holding includes 1,406,383 shares acquirable through convertible securities within 60 days, with …

Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake

Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have reported a 9.99% beneficial ownership stake in Unicycive Therapeutics, Inc. (UNCY). This stake, detailed in an amended Schedule 13G filing, comprises 4,856,259 shares, which includes common stock and shares convertible from …

Cycurion, Inc. 2026: Revenue $3.76M, EPS ($0.41) — 10-Q Summary

Cycurion, Inc. (CYCU) reported its 2026 quarterly results, showing revenue of $3.76 million and a diluted loss per share of ($0.41). The company achieved a narrower net loss compared to the prior year, attributed to an acquisition and improved margins. Business highlights include integrating …

PureCycle, IPL Schoeller launch SnapPack Square Evo container line

PureCycle Technologies and IPL Schoeller have introduced SnapPack Square Evo, a new line of tamper-evident packaging that incorporates 20 percent PureFive recycled polypropylene in each unit. This initiative provides brand owners with an off-the-shelf solution to meet increasing recycled-content requirements without extensive development time …

Cycurion Releases Q2 2026 Financial Results

Cycurion, Inc. (WAVS) reported its Q2 2026 financial results, showing a narrowed net loss of $4.0 million, or $0.41 per share, indicating improved profitability. Revenue for the quarter was $3.8 million, a slight decrease of 3.4% from Q2 2025, while the company continued to …

Cycurion earnings beat by $0.15, revenue topped estimates

Cycurion (NASDAQ: CYCU) reported a Q2 EPS of $-0.41, surpassing analyst estimates by $0.15, and revenue of $3.76M, which also topped consensus estimates. Despite this earnings beat, the company's stock price has significantly declined over the past three and twelve months. InvestingPro assesses Cycurion's …

Armistice Capital (BCYC) reports 3.40M Bicycle Therapeutics ADSs in 13G/A

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 3,398,000 American Depositary Shares (ADSs) of Bicycle Therapeutics plc (BCYC). This represents 6.72% of the outstanding class as of June 30, 2026. All voting and dispositive power over …

Cycurion beats revenue & EPS estimates; lands $54.6M 10-year contract, gross margin jumps to 29.1%

Cycurion (CYCU) reported strong Q2 results, exceeding revenue and EPS estimates. The company secured a significant $54.6 million, 10-year contract and saw its gross margin increase substantially to 29.1%. Acquisitions also contributed to a boosted revenue run rate.

Noble Financial Has Pessimistic View of UNCY Q2 Earnings

Cycurion (NASDAQ: CYCU) boosts margins, lands $54.6M contract in Q2 update

Cycurion (NASDAQ: CYCU) reported Q2 2026 revenues of $3.8 million, beating Wall Street estimates, and saw a significant improvement in gross margin to 29.1% from 6.1% year-over-year. The company also announced a landmark $54.6 million, 10-year contract and made strategic acquisitions, contributing to an …

Cyclerion Therapeutics (CYCN): Balyasny group discloses 7.33% equity position

Balyasny Asset Management L.P. and its affiliated entities have disclosed a 7.33% beneficial ownership stake in Cyclerion Therapeutics, Inc. (CYCN). The group holds 317,511 shares of common stock through Atlas Diversified Master Fund, Ltd., exercising sole voting and dispositive power over these shares. This …

Cyclopharm (ASX:CYC) Records Revenue Growth While US Technegas Rollout Progresses

H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $15

H.C. Wainwright has reiterated its Buy rating for Unicycive Therapeutics (UNCY.US) and maintained a price target of $15. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Hold" by Brokerages

Unicycive Therapeutics (NASDAQ:UNCY) has received a consensus "Hold" rating from seven brokerages, with an average 12-month price target of $21.75, despite recent target reductions and downgrades from some firms. The company reported a quarterly loss of $0.06 per share, beating analyst estimates, and institutional …

Atlas Cycles Q1FY27 net loss widens to ₹192 lakh on revenue drop

Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics reported its second-quarter 2026 financial results, with $61.4 million in cash, cash equivalents, and marketable securities, providing a runway into 2027. The company is focused on securing FDA approval for oxylanthanum carbonate (OLC) for hyperphosphatemia, with a facility inspection assigned for their …

Form 8K Cycurion Inc For: 12 August By Investing.com

This article reports on Cycurion Inc.'s Form 8K filing for August 12. It reiterates the filing information and includes a stock performance update for CYCU, which was up 12.90%. The content is brief and focuses on the official corporate filing.

Cyclerion (NASDAQ: CYCN) details Korsana merger plans and proxy materials

Cyclerion Therapeutics (NASDAQ: CYCN) has detailed its merger plans with Korsana Biosciences, outlining a two-step process where Korsana will become a wholly-owned subsidiary. The company filed Form 425 communications, which include forward-looking statements about Korsana's KRSA-028 program and THETA platform, expected closing timelines, future …

Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.5, Implies 550% Upside

Analysts have cut the average 12-month price target for Unicycive Therapeutics, Inc. (UNCY) stock from $37.5 to $32.5, with individual forecasts ranging from $13 to $61 per share. Despite the cut, the new target still implies a significant 550% potential upside based on the …

Unicycive Therapeutics (NASDAQ:UNCY) Announces Quarterly Earnings Results

Unicycive Therapeutics (NASDAQ:UNCY) reported a quarterly loss of $0.06 per share, significantly beating analyst expectations of a $0.47 loss. Following the positive earnings surprise, shares of UNCY traded up, and institutional investors have increased their holdings. Analyst sentiment remains mixed with a consensus "Hold" …

Form 8K Unicycive Therapeutics Inc For: 12 August By Investing.com

This article reports on the filing of a Form 8K by Unicycive Therapeutics Inc. on August 12. The brief announcement from Investing.com provides the date of the filing and the company name. The rest of the content includes market data, news headlines, and promotional …

IPL Schoeller & PureCycle Launch Off-the-Shelf Container Line, SnapPack Square EVO, Ahead of State Sustainability Mandates

PureCycle Technologies and IPL Schoeller have introduced SnapPack Square EVO, a new line of sustainable, tamper-evident containers incorporating 20% PureFive® recycled polypropylene. This initiative provides brand owners with an immediate solution to meet upcoming recycled content mandates, particularly New Jersey's law, and get ahead …

PureCycle's SnapPack Line Will Put Recycled Plastic in Every Container

PureCycle Technologies and IPL Schoeller have launched SnapPack Square EVO, a new tamper-evident container line featuring 20% PureFive® recycled polypropylene resin. This initiative aims to help brand owners meet increasing

Atlas Cycles Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Unicycive Therapeutics shares rise after second-quarter loss beats forecasts

Unicycive Therapeutics' shares rose after reporting a smaller-than-expected second-quarter loss of $0.06 per share, significantly beating the analyst consensus of $0.48 per share. The net loss narrowed to $1.7 million from $6.5 million due to a change in warrant liability fair value, despite increased …

Unicycive Therapeutics stock rises 2% on second quarter earnings beat

CYCU Q2'26 Earnings: EPS estimate is (0.56) USD

Cycurion, Inc. (CYCU) is scheduled to release its Q2'26 earnings on August 13, with an estimated revenue of $3.62 million and an EPS of ($0.56). The article provides a detailed table of past revenue and EPS figures, comparing reported numbers against estimates and highlighting …

Cycurion (NASDAQ: CYCU) sets Aug. 20 Panel hearing as Nasdaq listing review continues

Cycurion (NASDAQ: CYCU) has announced that its hearing before the Nasdaq Hearings Panel is scheduled for August 20, 2026, at 10:00 a.m. Eastern Time, to address its continued listing status. The company's common stock continues to trade on the Nasdaq Capital Market under the …

Cycurion confirms Aug. 20 Nasdaq hearing; common stock remains trading on Nasdaq

Cycurion (CYCU) has confirmed its Nasdaq Hearings Panel date for August 20, 2026, at 10:00 a.m. Eastern. The company's timely request for a hearing has halted the delisting process, allowing its common stock to continue trading on the Nasdaq Capital Market. A final decision …

Unicycive Therapeutics (UNCY) posts $14.5M H1 loss, raises $34M equity

Unicycive Therapeutics reported a net loss of $14.5 million for the first half of 2026, widening from $5.9 million in the prior year, primarily due to increased research and development and general and administrative expenses. Despite the larger loss, the company significantly boosted its …